Livsayis (cemdisiran) has been approved by the FDA for adults with AChR antibody-positive gMG, the most common form of the ...
MSD joins Johnson & Johnson, Novartis, and Eli Lilly among London-based Isomorphic's publicly announced R&D partners. While ...
Diabetes drug development has changed more in the last 10 years than in the previous three decades combined. Indeed, today, ...
Sanofi is already a big player in Gaucher disease, selling the ERT Cerezyme (imiglucerase) for all three types, as well as ...
The UK government has proposed changes to the definition of gene therapies and other genetic medicines, aiming to give ...
Novartis has raised its peak sales expectations for three key growth products – Kesimpta, Scemblix, and Leqvio – by around $4 billion as it targets 5% annual revenue growth between 2026 and 2031.
In a new pharmaphorum podcast, Nicole Raleigh caught up with Jane Li, vice president and general manager for companion ...
MILAN – 17th November 2026 - CPHI Milan has announced record attendance figures to this year’s major event, welcoming over 63 ...
MSD has called a halt to three trials of BTK inhibitor nemtabrutinib – added to its pipeline through its $2.7 billion ...
Donald Trump nominated Overton – a White House aide, physician, and vocal opponent of abortion – in the summer. The following ...
The UK government has said it will end the NHS's controversial contract with US tech firm Palantir, but not until 2029 – two ...
Real-World Evidence for the Impact of Company-Led Medical Education – Medscape Medical Affairs explores the question of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results